Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scahill, L.
Right arrow Articles by Peterson, B.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scahill, L.
Right arrow Articles by Peterson, B.S.

Neurology 2003;60:1130-1135
© 2003 American Academy of Neurology

A placebo-controlled trial of risperidone in Tourette syndrome

L. Scahill, MSN PhD, J.F. Leckman, MD, R.T. Schultz, PhD, L. Katsovich, MS and B.S. Peterson, MD

From the Child Study Center (Drs. Scahill, Leckman, Schultz, and Peterson, and L. Katsovich) and School of Nursing (Dr. Scahill), Yale University, New Haven, CT; and Columbia University (Dr. Peterson), New York, NY.

Address correspondence and reprint requests to Dr. Larry Scahill, Associate Professor of Nursing & Child Psychiatry, Yale Child Study Center, New Haven, CT 06520; e-mail: lawrence.scahill{at}yale.edu

Objective: To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome.

Methods: This was an 8-week, randomized, double-blind, placebo-controlled trial. The primary outcome measure was the Total Tic score of the Yale Global Tic Severity Scale (YGTSS).

Results: Thirty-four medication-free subjects (26 children and 8 adults) ranging in age from 6 to 62 years (mean = 19.7 ± 17.0 years) participated. YGTSS Total Tic scores were similar at baseline (26.0 ± 5.1 for risperidone vs 27.4 ± 8.5 for placebo). After 8 weeks of treatment (mean daily dose of 2.5 ± 0.85), the 16 subjects on risperidone showed a 32% reduction in tic severity from baseline, compared to a 7% reduction for placebo patients (n = 18) (F[2,64] = 6.07; p = 0.004). The 12 children randomized to risperidone showed a 36% reduction in tic symptoms compared to an 11% decrease in the 14 children on placebo (F[2,48] = 6.38; p = 0.004). Two children on risperidone showed acute social phobia, which resolved with dose reduction in one subject but resulted in medication discontinuation in the other. A mean increase in body weight of 2.8 kg was observed in the risperidone group compared to no change in placebo (F[2,64] = 10.68; p = 0.0001). No extrapyramidal symptoms and no clinically significant alterations in cardiac conduction times or laboratory measures were observed.

Conclusion: Risperidone appears to be safe and effective for short-term treatment of tics in children or adults with Tourette syndrome. Longer-term studies are needed to evaluate the durability of efficacy and safety over time.




This article has been cited by other articles:


Home page
 Am. J. PsychiatryHome page
R. Marsh, T. V. Maia, and B. S. Peterson
Functional Disturbances Within Frontostriatal Circuits Across Multiple Childhood Psychopathologies
Am J Psychiatry, June 1, 2009; 166(6): 664 - 674.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
Y. Arana-Lechuga, O. Sanchez-Escandon, N. de Santiago-Trevino, C. Castillo-Montoya, G. Teran-Perez, and J. Velazquez-Moctezuma
Risperidone Treatment of Sleep Disturbances in Tourette's Syndrome
J Neuropsychiatry Clin Neurosci, August 1, 2008; 20(3): 375 - 376.
[Full Text] [PDF]

Home page
 J Child NeurolHome page
W. G. Ondo, D. Jong, and A. Davis
Comparison of Weight Gain in Treatments for Tourette Syndrome: Tetrabenazine Versus Neuroleptic Drugs
J Child Neurol, April 1, 2008; 23(4): 435 - 437.
[Abstract] [PDF]

Home page
 J Atten DisordHome page
T. J. Spencer, F. R. Sallee, D. L. Gilbert, D. W. Dunn, J. T. McCracken, B. J. Coffey, C. L. Budman, R. K. Ricardi, H. L. Leonard, A. J. Allen, et al.
Atomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome
J Atten Disord, January 1, 2008; 11(4): 470 - 481.
[Abstract] [PDF]

Home page
 FocusHome page
G. Chouinard
The Search for New Off-Label Indications for Antidepressant, Antianxiety, Antipsychotic and Anticonvulsant Drugs
Focus, September 1, 2006; 4(4): 528.
[Full Text] [PDF]

Home page
 J Child NeurolHome page
M. B. Himle, D. W. Woods, J. C. Piacentini, and J. T. Walkup
Brief Review of Habit Reversal Training for Tourette Syndrome
J Child Neurol, August 1, 2006; 21(8): 719 - 725.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. Olfson, C. Blanco, L. Liu, C. Moreno, and G. Laje
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
Arch Gen Psychiatry, June 1, 2006; 63(6): 679 - 685.
[Abstract] [Full Text] [PDF]

Home page
 AutismHome page
C. Feroz-Nainar and M. Roy
Risperidone and late onset tics
Autism, May 1, 2006; 10(3): 302 - 307.
[PDF]

Home page
 Arch. Dis. Child.Home page
C R Steer
Managing attention deficit/hyperactivity disorder: unmet needs and future directions
Arch. Dis. Child., February 1, 2005; 90(suppl_1): i19 - i25.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
U. Chowdhury and I. Heyman
Tourette's syndrome in children
BMJ, December 11, 2004; 329(7479): 1356 - 1357.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.